other third update for morning discuss corporate everyone. matters. today results and advancing Thank you and Thanks, quarter us immuno-oncology we joining programs our Rachel. Good you as on our
field, platform partnering Our neoantigen on cure development and We creation Genocea development. through our vaccines, is discovery has which antigen focused own antigens critical antigens, of to to mount an patient's since against cancer cancer. clear, vaccine's the identify vaccines we're is vaccine vaccine correct both for response right the advantage ability value cancer immune and a of through new optimal our our from to help believe cancer cancer ability determinant comes in and the through a specifically the vision this vaccine a exciting having
is answer neoantigens, they in target wrong decisive So, There the the is what neoantigen a success works and right papers highlight if this two it companies, the so published and recently optimally. challenge straightforward. crucial proposition. all. But work were identification is me selecting greatest our our highlight if target, stimulates it vaccine response themselves what the of to vaccine right using assays, vaccine predicted patients' immunological to rigorous showed predicted against neoantigens. NEON patients antigens. they response most be barely and systems BioNTech, sub-optimally, should works the Nature Two Naturally, vaccinated immune an immune issue. at platform. the which why that the selection registered crucial? antigens such to that But misses technology, the vaccine explaining vaccine is selection vaccine us makes solve vaccine neoantigen so right different? It's one proprietary before to unique the a ATLAS, our neoantigen vaccine includes Identifying is field If Why perhaps neoantigen let with advantage we core The the in antigen antigens. in the
responses. the vaccine no proving much as So vaccines, come surprise in both concept, immunological the and for improvement that general clinical should leave while headroom it neoantigen
such the right identifying challenge are a interrelated There for is the two neoantigen field? why answers. So,
neoantigens. educated thousands in-silico through have cancers that cells different in-silico or for these to XX% of the dozens, may On each certain hundreds T double-digits are or candidate cells, high amount First, essential tools These thousands conventional of hundreds patient antigens. the tools a do the evidence immune candidate point on those And there second, tools will potential have that only system these are populations fundamentally guesswork CDX, from even largely predictive But antigens XX% so tools help many power limited. one, so-called are for meaning as based identifying killer assumptions is mutational many how to neoantigens for and flawed. CDXs. the predictive respond the candidate the and a in even to shifting have neoantigens, burden, personalized so mutations crack about CDX T not for
take knows can fact response there immune right that individual's why make ATLAS antigen antigen. why candidate one apart APCs every yet basis populations. T which With with is, exciting and ATLAS, true we cytokine cells per choose The T in why their is true find own power the what the T new to the neoantigens. ATLAS are educated work? not let because own cell leaders their the feed an ourselves truth of limited measurement are and antigen-presenting we into T field, limited showing tell on this a patient's Genocea we responses cells through are, T us to antigens the different own APCs cells. us neoantigen own are does cell set T cells making guesses, or a as tell is neoantigens in the We How cells per letting patient's We for type their a cancer we neoantigens no vaccines. chooses specific better lab. So predictive that And explains and
or further, beauty of works faithfully does true whether stimulate So inhibitory. all good if patients. importantly, and a the we it for it immune CDX mutation the cells in both CDX and And bad is away most cold is ATLAS and or neoantigen, meaning is system it neoantigen, right that can tell hot tumors, for T it's a any and specific
patient best type, neoantigens. cancer of choose or regardless believe have the we to So, we means
optimized of Higgins by Dr. is here Genocea family decade. Harvard, at at scientific past Our for founder, the been ATLAS Darren technology, a invented by has and our protected patents
continued develop over shows tools. which have data, to We we predictive superiority in-silico ATLAS' preclinical believe the
cell with cancer, about study, non-small For personalized a in isolated in lung instance, mutations. a patient we head-to-head XXX
in-silico While a positives, cells were were many T antigens predicted immune not that predicted, potentially patient's own that importantly, showed also inhibitory, ATLAS is other false do patient's neoantigens and the tools that shutting antigens not found large of recognize, number response. a standard off some showed we
SITC we'll its vaccines ATLAS' shared As some as today's identification will we data promise antigen release, new identification compelling highlight presenting mentioned press week's differentiation which for next in at well. and in neoantigen antigen ATLAS in Meeting, be
program, using expect each in will we on in in vaccine. XXXX. mutations also unique are patient GEN-XXX, feed of samples, cancer and that to we basis, we'll an In will those IND blood which file ATLAS We our tumor for first early trial personalized the our true vaccine per collect lead patient's all tumor, neoantigens potential candidate patient's neoantigens to we the then identify identify and to include into in ATLAS a
existing of variety in-human superior immunogenicity manufacture GEN-XXX of efficient then combining release deliver with point, study, for will demonstrate peptides manufacture no on vaccine patient's we long an relapse. but evidence will our this a relationships network And to and disease of synthetic and risk by we've which enable adjuvant. each patients of initially with patients. a We supply-chain high across vaccine cancer of built this aim of in types With first
will of in trial. also continue clinical We patients outcomes the the follow to
while next-generation later behind vaccine program As mechanism I an a stimulating and XXXX. both in We immune immunogenicity of on time anticipate anticipate program, expect with GEN-XXX, year optimized next readout response are an an vaccine XXXX, we next this at the aimed even with a cost reducing from GEN-XXX mentioned, greater delivery neoantigen additional trial then goods. half first IND in developing IND needle-to-needle and of an early pipeline the initial we the and
to So months, something milestones time Genocea, and not In its it's over next next-generation also a partner ATLAS, road vaccine potential the important we can but very with broadly. exciting have the XX that just GEN-XXX down programs. with also at we personalized XX for
where tumor-associated T have for tumor We studied have cell virus. we few early-stage widely in novel a identified antigens programs for types and EBV-related this in major cancers antigens
I soon the immunotherapy GEN-XXX, Phase Finally, are we are herpes. These course discussions recently remind seeking our will strategic for genital of we X-ready will audience, of we and announced the treatment candidate ongoing alternatives to for Jonathan update over as turn news material to quarter's to as questions. we have share. the market don't before discuss it I to we the financials the With why call that, up open
